|
KMID : 0377619880530120837
|
|
Korean Jungang Medical Journal
1988 Volume.53 No. 12 p.837 ~ p.843
|
|
|
Prognostic Significance of DNA Ploidy Level and Estrogen Receptor in Breast Cancer
|
|
|
|
|
Abstract
|
|
|
Paraffin embeded specimen of primary tumors from 17 breast cancer patient were evaluated for the DNA ploidy by DNA histogram and analysis using flow cytometry.
These parameters were compared with the pathological staging, biochemical presense of estrogen receptor and the presense or abscense of recurrence during 2 year period.
According to the pathological stage, stage IIA was 60% and IIB was, 40 % in recurred group, and stage JIB was 43 % and IIIA was 57 %in non-recurred group.
Most(88 %) of the breast samples demonstrated a peak population of diploid GO/G1 cells which contained 2C amounts of DNA.
The tumors were classified into four DNA histogram types based on their DNA index distributions established by Auer.
These results showed that 17.6 % of the tumors were diploid (I) and indistinguishable from the diploid population of normal breast cells, 17.6 % were tetraploid(II), 41.2 % were hyperdiploid. (III), 23.6 % were irregular aneuploidy((IV).
The DNA index values varied from 0.45 (hypo diploid) to 3.74 (hyper hexaploid). The percentage of S-phase cells were 3.5 % in the diploid tumors and 14.3 % in the aneuploid tumors. Among patients who had recurred cancer during the 24 months follow-up, 85.7 % were classified in one of the aneuploid groups.
Rates of diploidy and aneuploidy among the non-recurrent groups were 20 % and 80 %, respectively. One of the patients who had local recurred cancer was hyperdiploid and the other was multiploid(IV) and all of the patients who had systematically recurred cancer were tetraploid(II). 20 % of recurred group were estrogen receptor positive and 70 % of nonrecurred group were estrogen receptor positive.
Our results demonstrated the value of using flow cytometry and steroid receptor value as supplements to histopathology for the characterization of subgroups of mammary cancer patients. The ability to identify patients with a good prognosis compared to those at high risk of recurrence will be valuable in the design of future prospective treatment studies.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|